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A new phospholipase A2 (PLA2)-inhibitory protein was isolated from the plasma of Atropoides nummifer, a crotaline snake from Central
America. This inhibitor was named AnMIP, given its ability to neutralize the activity of basic PLA2 myotoxins of its own and related venoms. The
cDNA of AnMIP was cloned and sequenced, showing that it belongs to the α group of phospholipase A2 inhibitors (PLIs). AnMIP appears as a
homotrimer in the native state, held together by non-covalent forces, with a subunit molecular mass of 22,247–22,301 and an isoelectric point of
4.1–4.7. This trimeric structure is the first observed in a PLIα from American crotaline snakes, previously reported only in Asian species.
Sequencing, mass spectrometry, and analytical isoelectrofocusing indicated the existence of isoforms, as reported for other PLIαs isolated from
snake plasma. The inhibitory profile of AnMIP showed specificity towards group II PLA2s, either belonging to the catalytically-active (D49) or
-inactive (K49) subtypes, exemplified in this study by Bothrops asper myotoxin I and A. nummifer myotoxin II, respectively. By phylogenetic
analysis it was shown that AnMIP is closely related to CgMIP-II, previously isolated from the plasma of Cerrophidion godmani, showing 93%
amino acid sequence identity.
© 2006 Elsevier Inc. All rights reserved.Keywords: Atropoides nummifer; Phospholipase A2; Myotoxin; Inhibitor; PLI-alpha; Snake venom1. Introduction
Phospholipases A2 (PLA2s) [E.C. 3.1.1.4] catalyze the Ca
2+-
dependent hydrolysis of the sn-2 ester linkage of gliceropho-
spholipids, yielding fatty acids and lysophospholipids. Based
on their primary structure and disulfide bond pattern, PLA2s
have been classified into eleven groups (Six and Dennis, 2000).
Secretory PLA2s present in snake venoms depend on a
conserved catalytic network and a water molecule for their
enzymatic activity (Berg et al., 2001). Snake venom PLA2s can
induce a variety of pharmacological effects by mechanisms that
are either dependent or independent of their catalytic activity,
such as neurotoxicity, myotoxicity, anticoagulant effect, platelet⁎ Corresponding author. Fax: +506 292 0485.
E-mail address: blomonte@cariari.ucr.ac.cr (B. Lomonte).
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doi:10.1016/j.cbpb.2006.09.003aggregation or inhibition, hemolytic, hypotensive and edema-
inducing activity (Kini, 2003). Variants of PLA2s in which D49
is substituted, mainly by K49, have been described in Viperidae
snake venoms. Despite lacking phospholipolytic activity, these
K49 PLA2 homologues display in vivo and in vitro pharmaco-
logical activities associated with their ability to interact with and
to destabilize biological membranes (Lomonte et al., 2003).
The natural resistance of snakes to the toxic components of
their own venoms, or to those of other species, has been
attributed to several mechanisms, including the presence of
neutralizing protein factors in their blood plasma (Fortes-Dias
et al., 1994; Perales et al., 1995; Faure, 2000). Toxin-inhibitory
proteins have also been found in the blood of mammals (Pérez
and Sánchez, 1999; Rocha et al., 2002). The PLA2 inhibitors
(PLIs) or myotoxin-inhibitory proteins (MIPs) isolated from
snake plasma are proteins that inhibit the enzymatic and/or
toxic activities induced by venom PLA2s. Based on their
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three groups, namely α, β, and γ (Ohkura et al., 1997). The
structural determinants that define each group include: a region
homologous to the carbohydrate recognition domain (CRD) of
C-type (Ca2+-dependent) lectins, in PLIαs; the presence of nine
leucine-rich tandem repeats, flanked by cysteine and proline-
rich clusters, for PLIβs; and two repeats of a cystein pattern
characteristic of the three-finger motifs, in PLIγs (Lizano et al.,
2003).
PLIαs are oligomers, each subunit consisting of 147
residues, with an N-glycosylation site at N103, four half-
cystines at positions 64–141 and 119–133, and molecular
masses ranging from 18 to 25 kDa (Lizano et al., 2003).
PLIαs have been isolated from Trimeresurus flavoviridis
(Kogaki et al., 1989), Agkistrodon blomhoffii siniticus (Ohkura
et al., 1993), Bothrops asper (Lizano et al., 1997), Cerrophi-
dion godmani (Lizano et al., 2000), and Bothrops moojeni
(Soares et al., 2003). In addition, a homologous protein, but
lacking inhibitory activity, has been isolated from the non-
venomous snake Elaphe quadrivirgata (Okumura et al.,
2003).
The CRD-like domain of PLIαs presents homology with
other members of the C-type lectin-like domain (CTLD) family
(Drickamer, 1999), including proteins that are able to interact
with PLA2s, such as the pulmonary surfactant apoprotein A
(Fisher et al., 1994), the M-type PLA2 receptor (Lambeau and
Lazdunski, 1999) and its soluble form (Higashino et al., 2002).
PLIα binding to PLA2 is independent of calcium (Kogaki et al.,
1989; Okumura et al., 2005), and of PLI glycosylation
(Nobuhisa et al., 1998; Soares et al., 2003).
By partial deletion analysis, a positive interaction between T.
flavoviridis PLIα and acidic PLA2s was mapped to the CTLD
region, and this binding capacity was further restricted to the C-
terminal 136–147 residues (Nobuhisa et al., 1998). In this
region, two hydrophobic tripeptides (Nobuhisa et al., 1998) and
the residue Y144 (Okumura et al., 2005) were shown to be
involved in the interaction. Based on chimeras between A.
blomhoffii siniticus PLIα and E. quadrivirgata PLI-like protein,
as well as site-directed mutagenesis studies, Okumura et al.
(2005) proposed that PLIαs form a trimeric structure, in which
the variable amino-terminal region positioned previous to the
conserved CTLD is responsible for trimerization, and subse-
quent formation of a central pore, which would be the structure
responsible for PLA2 binding. According to this model,
variations in the region 13–36 would contribute to the spec-
ificity of the inhibitor towards distinct PLA2s, whereas residues
located near the central pore, including those in the C-terminal
region, would directly interact with the PLA2 (Okumura et al.,
2005).
Atropoides nummifer is a crotaline snake distributed along
the Central American isthmus, commonly known as “jumping
viper” or “mano de piedra” (Solórzano, 1989). Two basic K49
PLA2s homologues, myotoxins I (Gutiérrez et al., 1986) and II
(Angulo et al., 2000), have been isolated from its venom. In this
work we report the isolation, characterization and molecular
cloning of a new myotoxin-inhibitory protein, AnMIP, present
in the blood plasma of this species.2. Materials and methods
2.1. Purification of PLA2 myotoxins
Crude venoms of A. nummifer and B. asper, respectively,
were pools obtained from at least twenty specimens collected in
Costa Rica and kept at the serpentarium of the Instituto
Clodomiro Picado, University of Costa Rica. A. nummifer
myotoxins I (Gutiérrez et al., 1986) and II (Angulo et al., 2000),
as well as B. asper myotoxin I (Gutiérrez et al., 1984), were
purified as originally described, by cation-exchange chroma-
tography on carboxymethyl-Sephadex C-25 (Pharmacia). Ho-
mogeneity of the toxins was assessed by polyacrylamide gel
electrophoresis in the presence of sodium dodecylsulphate
(SDS-PAGE; Laemmli, 1970) and by reverse-phase high
performance liquid chromatography (RP-HPLC) on a C4
column (250×4.6 mm; Vydac), eluted at 1.0 mL/min with a
gradient from 0 to 60% acetonitrile in 0.1% trifluoroacetic acid
(TFA). Purified taipoxin, a group I PLA2 from the venom of
Oxyuranus scutellatus (Fohlman et al., 1976), was kindly
donated by Dr Ivan Kaiser, University of Wyoming. Bee (Apis
mellifera) PLA2 (Shipolini et al., 1971), a group III PLA2, was
purified from crude venom (New Techniques Laboratory) by
RP-HPLC on a C8 column (250×10 mm; Vydac), eluted at
2.0 mL/min with a gradient from 0 to 60% acetonitrile in 0.1%
TFA.
2.2. Purification of AnMIP
An affinity matrix was prepared by coupling a mixture of
purified A. nummifer myotoxins I and II (12 mg of each) to an
NHS-activated HiTrap HP column (5 mL), following the
manufacturer's instructions (Amersham Biosciences). For the
purification of AnMIP, blood was collected from three adult
A. nummifer specimens using 0.38% (w/v) sodium citrate as
anticoagulant, and the plasma was separated by centrifugation
and stored at −20 °C. Plasma aliquots of 2 mL were diluted 1:5
in PB buffer (0.1 M sodium phosphate, pH 7.2), and recirculated
through the affinity column during 2 h at a flow rate of 1 mL/
min. After extensive washing of the column with PB buffer until
the eluent absorbance at 280 nm returned to baseline, the bound
protein fraction was eluted with 0.1 M glycine-HCl, pH 2.8, and
collected in tubes containing 0.5 M Tris–HCl, pH 8.8. This
fraction was finally concentrated by ultrafiltration under
nitrogen pressure, using PBS (0.04 M sodium phosphate,
0.12 M NaCl, pH 7.2) and a size-exclusion membrane with a
molecular mass cutoff of 10 kDa (Amicon). Protein concentra-
tion was determined by the micro-BCA method (Pierce) using
bovine serum albumin (BSA) as a standard. Homogeneity was
assessed by SDS-PAGE and RP-HPLC. This myotoxin-binding
protein, named AnMIP, was aliquoted and stored at −20 °C.
2.3. Biochemical and immunochemical characterization of
AnMIP
The subunit composition and molecular mass of AnMIP were
estimated by SDS-PAGE under reducing (2-mercaptoethanol,
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followed by Coomassie blue R-250 staining. A set of molecular
mass markers (Pharmacia) was included as a reference.
The molecular mass of the oligomeric protein in its native
state was estimated by analytical gel filtration chromatography
on a Superdex 200 HR 10/30 column, using an FPLC system
(Pharmacia Biotech) with PBS pH 7.2 as eluent, at a flow rate of
0.4 mL/min. A calibration curve was constructed by running
standard proteins (Pharmacia Biotech) under identical condi-
tions.Kav was calculated by the equationKav=(Ve−V0) / (Vt−V0),
where Ve is elution volume, V0 is void volume, and Vt is total
column volume. Analyses were performed in triplicate.
Chemical cross-linking was utilized to assess the number of
subunits composing the oligomeric protein. AnMIP was
incubated for 2 h at 37 °C in the presence of increasing con-
centrations of the homobifunctional agent bis(sulfosuccinimi-
dyl) suberate (BS3, Sigma), in 50 mM HEPES buffer, pH 7.5
(Staros, 1982). Then, the different samples were analyzed by
SDS-PAGE under reducing conditions, as described above.
The molecular mass of AnMIP was determined by electro-
spray ionization (ESI)-mass spectrometry on a LCQDuo
Finnigan ion trap instrument equipped with a nano-electrospray
ionization source, as described by Barona et al. (2006). The
amino-terminal sequence of AnMIP was determined by direct
Edman degradation on PVDF-adsorbed protein, on an Applied
Biosystems 494 amino acid sequencer, operated according to the
manufacturer's instructions.
The isoelectric point of AnMIP was determined by analytical
isoelectrofocusing in polyacrylamide gels containing carrier
ampholytes in the pH range 2.5–6.5 (Pharmacia Biotech) on a
mini-IEF cell (Bio-Rad Laboratories) at 100 V for 15 min,
followed by step increases to 200 V for 15 min and 450 V for
60 min. Protein markers of known pI values (Pharmacia) were
included as a reference.
Glycosylation of AnMIP was determined by dot-blotting, as
described by Keren et al. (1986). Three microgram of purified
AnMIP, B. asper myotoxin I (negative control), or A. mellifera
PLA2 (positive control), respectively, were adsorbed onto a
nitrocellulose membrane strip. Excess binding sites on the
membrane were saturated with 2% BSA-PBS for 30 min. After
washing with 0.2% BSA-PBS, oxidation of carbohydrates was
performed by adding 1% periodic acid-PBS for 1 h. The solution
was washed thoroughly, and the resulting aldehydes were
reacted with a peroxidase-hydrazide conjugate (52 mU/mL)
(Sigma) in 0.2% BSA-PBS for an additional hour. After
washing the unbound conjugate, color was developed with
H2O2/4-chloro-1-naphtol substrate.
Antigenic cross-reactivity between AnMIP and the previ-
ously characterized BaMIP (Lizano et al., 1997) was assessed by
enzyme-immunoassay. Wells of microtiter plates were coated
overnight with 0.2 μg of either AnMIP or BaMIP, diluted in
100 μl of 0.1 M Tris, 0.15 M NaCl, pH 9.0. After washing with
FALK buffer (0.05 M Tris, 0.15 M NaCl, 20 μM ZnCl2, 1 mM
MgCl2, pH 7.4) wells were blocked with 100 μl of 1% BSA-
FALK for 30 min. After decanting, 100 μl of rabbit anti-BaMIP
serum (1:1500) (Lizano et al., 1997), or a normal rabbit serum
control, were incubated for 1 h. After washing, 100 μl of a goatanti-rabbit immunoglobulins-alkaline phosphatase conjugate
(1:2000) were incubated for an additional hour. Color was
developed with p-nitrophenylphosphate and recorded at 410 nm
on a Multiskan microplate reader (Flow Laboratories). Samples
were assayed in triplicate wells.
2.4. Inhibitory activity of AnMIP
In all inhibition experiments, the inhibitor was incubated with
the corresponding PLA2 or PLA2-homologue toxin for 30 min at
room temperature, in PBS. Molar ratios were calculated on the
basis of reported molecular mass values of each PLA2, the
subunit mass of AnMIP obtained by mass spectrometry, and the
oligomeric state information obtained by chemical cross-linking
studies. Analyses were performed in duplicate.
PLA2 activity was determined using egg yolk phospholipids
as substrate, followed by extraction and titration of the released
fatty acids as described by Dole (1956). Enzymatic activity was
also assessed by an indirect hemolysis assay in agarose gels
containing egg yolk phospholipids (Gutiérrez et al., 1988).
PLA2s belonging to groups I (taipoxin, 1 μg), II (B. asper
myotoxin I, 10 μg), and III (bee venom PLA2, 0.25 μg) were
tested. The enzyme amounts selected correspond to the linear
regions of previously established concentration-activity calibra-
tion curves.
Myotoxic activity was evaluated in vitro, by quantifying the
cytolysis of confluently growing myotubes differentiated from
the murine myoblast cell line C2C12 (ATCC CRL-1772), as
described by Lomonte et al. (1999). In brief, after aspiration of
the growth medium, myotoxins alone, or preincubated with
AnMIP, were added to the cultures in 96-well plates and
incubated at 37°C. After 3 h, the release of lactate dehydroge-
nase to supernatants was determined by a kinetic assay (LDH-P
mono, Biocon Diagnostik). Controls for 0% and 100% cytolysis
consisted of medium alone, and 0.1% Triton X-100, respective-
ly. AnMIP was tested against A. nummifer myotoxin II and B.
asper myotoxin I, using a challenge dose of 20 μg/well.
2.5. cDNA cloning and sequencing
Total RNA was isolated from A. nummifer liver with the
NucleoSpin RNA L kit (Macherey-Nagel) according to
manufacturer's instructions. cDNA synthesis was carried out
with the RevertAid H Minus First Strand cDNA Synthesis kit
(Fermentas Life Sciences), using Oligo(dT)18 primers. Primers
complementary to the consensus non-coding sequences flanking
the reading frames of reported inhibitors were used for the PCR
amplification. Primer sequences were as follows: α-F 5'-
ACCGCAGAGTTTAAAGATG-3', α-R 5'-GCCGGTC-
TTCCTTCT-3'; β-F 5'-GAAAGATACAGGATG-3', β-R 5'-
TTCAGGTAACAGGTG-3' (both pairs of primers designed
with the Oligo Primer Analysis Sofware 4.04; Wojctech
Rychik), and γ-F 5'-ATCCTCACTAAAGAGCCA-3', γ-R 5'-
GGATGAAATTGCTGACCT-3', as reported by Lizano et al.
(2000). PCR amplification reactions were carried out with the
low error-prone Pfu DNA polymerase (Fermentas). Cycling
conditions were as follows: 4 min at 94 °C, followed by
Fig. 1. A. SDS PAGE analysis of AnMIP under non reducing (NR) and reducing (R) conditions. MMM: molecular mass markers (mass indicated to the left). B. Molecular
mass determination for native AnMIP (n) by gel filtration chromatography. The molecular masses of the markers (•) utilized for the calibration curve are indicated.Kav is
defined in Materials and methods. C. Chemical cross linking analysis for AnMIP. The inhibitor was incubated with increasing concentrations (as indicated in the bottom of
the gel) of bis(sulfosuccinimidyl)suberate, and then analyzed by SDS PAGE. MMM: molecular mass markers (mass indicated to the left).
Fig. 2. Cross reactivity between AnMIP and BaMIP evaluated with a rabbit
antiserum elicited against BaMIP (anti BaMIP), by enzyme immunoassay.
Control serum corresponds to a non immune rabbit. Bars represent mean±SD of
triplicate wells.
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γ inhibitors, respectively, and 2 min at 72 °C. Following the last
cycle, Taq DNA polymerase (Pharmacia Biotech) was added
and incubated for 20 min at 72 °C, in order to incorporate poly
(A) tails to the blunt-ended PCR products generated by the Pfu
DNA polymerase. PCR products were analyzed by 1.5%
agarose gel electrophoresis in 0.89 M Tris, 0.89 M boric acid,
0.02 M EDTA-Na2, pH 8.0 buffer (TBE), and visualized with
ethidium bromide. For the PCR amplification, clones containing
the α CgMIP-II (Lizano et al., 2000), β Abs-PLI (Okumura et
al., 1998) and γ CgMIP-I (Lizano et al., 2000) were utilized as
reaction controls. The reaction products were purified with a
DNA extraction kit (Fermentas), following manufacturer's
instructions. Ligation to the plasmid pTZ57R/T and transfor-
mation of XL1-Blue Escherichia coli cells were performed with
the InsT/Aclone PCR Product Cloning kit (Fermentas). Plasmid
DNA purification was performed with the NucleoSpin Plasmid
kit (Macherey-Nagel). Sequencing reactions were carried out
with the ABI PRISM BigDye Terminator v3.1 Cycle Sequenc-
ing kit (Applied Biosystems), and analyzed with an ABI PRISM
310 Genetic Analyzer. Four clones, obtained from two
independent retrotranscription and amplification reactions,
were sequenced in both senses, with the same primers utilized
for the PCR amplification. Manual depuration and analysis of
the sequences was performed with the BioEdit Sequence
Alignment Editor (Hall, 1999).
2.6. Multiple sequence alignment and phylogenetic analysis
Multiple sequence alignment of PLIαs was performed with
Clustal W (Thompson et al., 1994). Sequences included in the
alignment were the following (when available, NCBI database
accession numbers are indicated in square brackets; other se-
quences were obtained from the literature): A. nummifer AnMIP
(present study) [DQ657241], T. flavoviridis PLIα, subunits A
and B (Inoue et al., 1991) [P21755 and P21756, respectively],
Agkistrodon blomhoffii siniticus PLIα (Okumura et al., 1999)
[BAA86973.1], B. asper BaMIP (Lizano et al., 1997) [P81077],
C. godmaniCgMIP-II (Lizano et al., 2000), B. moojeni BmjMIP
(Soares et al., 2003) [JC7936] and E. quadrivirgata PLIα-like
protein (Okumura et al., 2003) [BAC53925.1]. Phylogenetictrees were calculated using PROTDIST and NEIGHBOR
(Felsenstein, 1995) and drawn with TreeView 1.6.6 (Page,
1996). Caenorhabditis elegans hypothetical protein Y48E1B.9
(C. elegans Sequencing Consortium, 1998) [Y48E1B.9] was
included as an outgroup.
3. Results
3.1. AnMIP purification and characterization
AnMIP was purified from the plasma of A. nummifer by
affinity chromatography using a mixture of the two basic PLA2
myotoxins present in the venom of this species, which are
closely related Lys49 isoforms. From 20 mL of plasma,
approximately 1.6 mg of AnMIP was recovered. The inhibitor
appeared as a band of approximately 26 kDa under reducing
conditions, whereas it migrated as a band of 19 kDa under non-
reducing conditions, in SDS-PAGE (Fig. 1A). Using gel
filtration chromatography, the molecular mass of the native
protein was estimated to be 92 kDa (Fig. 1B). This was in
agreement with chemical cross-linking analysis, where BS3 was
able to covalently stabilize a proportion of the AnMIP subunits
as dimeric (∼50 kDa) and trimeric (∼80 kDa) structures
(Fig. 1C), which did not dissociate under the reducing conditions
of SDS-PAGE. No multimeric structures of higher mass were
Fig. 3. Inhibition of the cytolytic activity of B. asper myotoxin I (A) and
A. nummifer myotoxin II (B) on confluently growing myotubes, differentiated
from the murine myoblast cell line C2C12 (ATCC CRL 1772), by AnMIP.
Values are expressed relative to 0% cytolysis control (PBS) and 100% cytolysis
control (0.1% Triton TX 100), as described in Materials and methods. The
myotoxin:AnMIP molar ratios are indicated in parentheses. Bars represent
mean±SD of duplicate cultures.
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AnMIP to be a trimeric protein.
Analytical isoelectrofocusing of AnMIP resolved two bands,
corresponding to pI values of 4.1 and 4.7, respectively (not
shown). By means of a sensitive hydrazide-peroxidase conju-
gate assay, AnMIP tested positive for glycosylation. In addition,
AnMIP showed a significant antigenic cross-reactivity with
BaMIP, an α-type inhibitor (Fig. 2), by enzyme-immunoassay.
Antibodies to BaMIP recognized AnMIP with a signal of
approximately 45% of that obtained with the homologous
antigen (Fig. 2), therefore suggesting AnMIP to belong to the
group α inhibitors.
3.2. Inhibitory activities of AnMIP
The ability of AnMIP to inhibit the myotoxic activity of snake
venom PLA2s was evaluated in vitro, using cultured myotubes
as targets. As shown in Fig. 3, AnMIPwas able to reduce by 67%
and 93% the toxic activity of A. nummifer myotoxin II and B.
asper myotoxin I, respectively, when preincubated at a molar
ratio of 1:1. At an AnMIP:toxin molar ratio of 1:3, a 45%
reduction in the activity of A. nummifer myotoxin II was
obtained, whereas the effect of B. asper myotoxin I remained
unchanged (Fig. 3). The limited amounts of purified AnMIP
precluded testing its inhibitory action at molar ratios higher than
1:1. Myotube cultures exposed to AnMIP alone, at the higher
concentration utilized in inhibition tests, did not present
microscopical alterations or increases in LDH activity in
comparison to control cultures exposed to medium alone.
Inhibition of PLA2 activity by AnMIP was evaluated on egg
yolk phospholipids, either titrimetrically or by an indirect
hemolytic test in agarose gels. Given the absence of basic D49
PLA2s in A. nummifer venom, myotoxin I from B. asper, a
related crotaline species, was utilized as a representative of
group II PLA2s. When preincubated at a molar ratio of 1:1,
AnMIP inhibited the enzymatic activity of B. asper myotoxin I
by 42%. No inhibition was observed at an AnMIP:toxin molar
ratio of 1:3 (not shown). On the other hand, the group I PLA2
taipoxin, and the group III bee venom PLA2 were not inhibited
by AnMIP at a molar ratio of 1:1. Increasing the AnMIP:toxin
molar ratio to 2:1 did not inhibit the enzymatic activity of
taipoxin, whereas a slight decrease of about 25% was observed
for the bee venom enzyme (not shown).
3.3. cDNA cloning, sequencing and phylogenetic analysis
Total RNA from A. nummifer liver was isolated in order to
generate cDNAs. A 500 bp product was amplified and cloned.
Four clones, obtained from two independent retrotranscription
reactions, were randomly selected for bidirectional nucleotide
sequencing. Two different sequences were obtained, and the
nucleotide and deduced amino acid sequences for both variants
of AnMIP are presented in Fig. 4. As shown, six nucleotide
substitutions were found among these sequences. Three such
substitutions implied amino acid changes in the mature coding
region, predicting a sequence identity of 97% among both
variants. The deduced amino acid sequence presented a 19amino acids putative signal sequence, typical of secreted pro-
teins. The deduced mature sequences are 147 residues long,
presenting the conserved cysteine residues at 64, 119, 133, and
141, and the putative glycosylation site at N103, characteristic of
PLIαs. The deduced N-terminal sequence was corroborated by
direct amino acid sequencing, up to the 10th residue, showing
the sequence DEKDSDVQML.
The deduced amino acid sequences of the two isolated clones
predict theoretical molecular masses of 16,378.2 and 16,466.3,
respectively. By ESI-MS, two main signals corresponding to
mass values of 22,247.0 and 22,301.0 were obtained. The
difference between the predicted and the observed molecular
mass values would be caused by the glycosylation of the
protein.
The AnMIP sequence was aligned with those of other PLIαs,
as presented in Fig. 5. From residues 49 to 143 themature protein
presents the CTLD, the most conserved region among these
inhibitors. There is a high sequence similarity among inhibitors,
except in the case of EqPLI-LP, the homologous non-inhibitory
protein from E. quadrivirgata. The C. elegans hypothetical
protein Y48E1B.9 (CeCLECT), a homologue of the α group
PLIs, was used as an outgroup to derive an evolutionary tree
from this alignment (Fig. 6). It shows that inhibitors from the
Fig. 4. cDNA nucleotide sequence (lowercase) and deduced amino acid sequence (uppercase) of AnMIP, clones 1 and 2 (DQ657241). Sequences of the primers used
for the amplification are double underlined, and the initiation and termination codons are in boldface. The signal peptide is underlined. The differences found in clones
3 and 4 (DQ657242) relative to clones 1 and 2 are shaded in gray for the nucleotide sequence, and in black for their deduced amino acid sequences. The numbering
corresponds to the mature protein sequence.
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esurus snakes, which are distributed only in Asia, and closer to
the PLI from Agkistrodon, a genus present both in the Asian andFig. 5. Multiple sequence alignment for PLIαs using the CLUSTALWalgorithm. Iden
cystines are in bold, and the CRD like domain is upper lined. Identity percentages rela
37–147 are indicated for each inhibitor. The accession numbers and references for tAmerican continents. Furthermore, the tree also shows that
AnMIP is phylogenetically closest to CgMIP-II, the C. godmani
PLIα inhibitor.tical residues are shaded in black, and conserved residues in gray. Conserved half
tive to AnMIP (DQ657241) for the complete protein and the segments 1–36 and
he proteins included in the alignment are described in Materials and methods.
Fig. 6. Phylogenetic tree relating AnMIP to others PLIαs. The primary
structures were aligned with CLUSTAL W, and the tree was built with
PROTDIST and NEIGHBOR, using the sequence of C. elegans hypothetical
protein Y48E1B.9 (CeCLECT) as an outgroup. The accession numbers and
references for the proteins included in the tree are described in Materials and
methods.
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amplification, in attempts to search for such type of inhibitors in
mRNA extracted from the liver tissue of A. nummifer.
4. Discussion
A new PLA2 inhibitory protein was isolated from the plasma
of A. nummifer, a crotaline snake from Central America. This
inhibitor was named AnMIP, given its ability to neutralize the
activity of myotoxic components of its own and related venoms.
AnMIP presented physicochemical properties characteristic of
PLIαs, as well as significant cross-reactivity with antibodies
elicited against an α inhibitor (BaMIP). Further direct amino-
terminal and cDNA sequencing confirmed its classification as a
new member of the PLIα group.
The inhibitory profile of AnMIP is characteristic of PLIαs,
with a specificity towards group II PLA2s, either belonging to the
catalytically-active (D49) or -inactive (K49) subtypes, exempli-
fied in this study by B. asper myotoxin I and A. nummifer
myotoxin II, respectively. In agreement with the inhibitory
behavior of PLIαs, AnMIP did not affect the catalytic activity of
taipoxin (group I), while it decreased only slightly that of bee
venom PLA2 (group III). This is in clear contrast to PLIγs, in
particular those isolated from elapid snakes, which display a
broad inhibitory profile against all three structural groups of
venom PLA2s (Lizano et al., 2003). Despite several attempts
under controlled PCR conditions, no amplification of PLIβ or γ
cDNAs fromA. nummifer liver was achieved. However, this does
not preclude the possibility of the presence of such types of
inhibitors in this snake species.
Previous studies have reported PLIαs from American
crotaline snakes to be composed of four to five subunits (Lizanoet al., 1997, 2000; Soares et al., 2003), the Asian crotaline
protein TfPLIα to be a heterodimer (Inoue et al., 1991), and the
Asian AbsPLIα and EqPLI-LP to be trimers (Ohkura et al.,
1993; Okumura et al., 2003). Given this diversity of oligomeric
structures, the subunit composition of the newly isolated AnMIP
was studied. Results of analytical gel filtration in the native state,
together with chemical cross-linking analyses, are consistent
with a trimeric structure for AnMIP, in agreement with the model
proposed by Okumura et al. (2005). This finding shows for the
first time that a trimeric quaternary structure can be found in
PLIαs of an American crotaline snake. The dissociation of
subunits in SDS-PAGE under non-reducing conditions
evidenced that the AnMIP trimer is held together by non-
covalent forces, in similarity with the cases of AbsPLIα and
EqPLI-LP (Ohkura et al., 1993; Okumura et al., 2003).
The full sequence of AnMIP was determined through cDNA
cloning from liver mRNA. Three amino acid differences were
found among the two sequences obtained by molecular cloning,
at positions 29, 31, and 109. The first two differences are located
in the most variable region of the mature protein, while the third
lies in the conserved CTLD region. In all cases, however, the
variations were conservative. Analytical isoelectrofocusing of
the purified AnMIP protein resolved two bands, corresponding
to estimated pI values of 4.1 and 4.7, respectively. Since the
deduced amino acid differences found in the two cDNAs clones
are conservative, this observation opens the possibility that
glycosylation variants affecting the net charge of this protein
may add to the observed microheterogeneity of AnMIP. Indeed,
the sequence of AnMIP presented the known glycosylation site
of PLIαs at position N103, and the protein was shown to be
glycosylated, suggesting that the difference between the subunit
molecular mass determined by ESI-MS and its predicted mass
should be accounted by glycosylation.
Taken together, evidence from isoelectrofocusing, cDNA
sequencing, and mass spectrometry, suggests the existence of
AnMIP isoforms. It should be noted that the physicochemical
characterization was performed on protein purified from pooled
plasma of a few specimens, while cloning was performed from
the liver of a single specimen. Both intraindividual and inter-
individual microheterogeneity could explain the presence of
isoforms. Similarly, previous reports have described isoforms in
Abs PLIα(Okumura et al., 1999) and CgMIP-II (Lizano et al.,
2000), based upon the sequencing of two cDNA clones in the
former case, or the differences between deduced and direct N-
terminal sequences in the latter. The presence of isoforms both in
plasma and at the level of liver transcripts was also documented
in the case of PLIγs, and it has been suggested that such minor
structural changes may play a subtle role in the recognition of
different PLA2 variants (Dunn and Broady, 2001). In the same
way, it is reasonable to assume that amino acid variability of
AnMIP and other PLIαs could widen the range of interaction
with diverse venom toxins.
Comparison of the primary structures of AnMIP and other
PLIαs (Fig. 5) showed amino acid identity values in the range of
65 to 93%, the non-inhibitory PLI homologue of E. quad-
rivirgata presenting the lower percentage. When only the more
conserved region 37–147 was analyzed, identities ranging from
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residues resulted in scores ranging from 36 to 86%. In this more
variable region, CgMIP-II presented a considerable identity
(86%) to AnMIP, as compared to the other PLIαs (61% or
lower). Interestingly, C. godmani myotoxin II presents 90%
sequence identity to A. nummifer myotoxin II, being the most
closely-related myotoxin by phylogenetic analysis (Angulo et
al., 2002). On the other hand, BaMIP, a crotaline PLIα,
presented a lower identity when a partial sequence was com-
pared to AnMIP (52% for residues 1–36). This would be in
agreement with the limited antigenic cross reactivity observed
among these two proteins by enzyme immunoassay (46%).
It has been reported that PLIαs isolated from American
crotaline snakes are more selective towards basic PLA2s (Lizano
et al., 1997, 2000), while those of Asian species preferentially
interact with acidic PLA2s (Inoue et al., 1997). Upon inspection
of the aligned sequences of PLIαs, no evident amino acid
changes could be ascribed to this reported difference in inhib-
itory profiles. An intraspecific specialization of the inhibitor
towards particular PLA2s co evolving in its own venom would
seem a more reasonable explanation than an early subdivision of
the specificity of these inhibitors in Asian and American
crotalines. Nevertheless, this hypothesis remains to be addressed
in future studies, as a larger number of inhibitors become
available for the detailed characterization of their structure–
function and evolutionary relationships.
Among the residues found only in AnMIP (V7,M9, R42, E84
for all clones, H29 for clones 1 and 2, and an V109 for clones 3
and 4), as compared to other PLIαs, four are located in the more
variable region, being in most cases conservative of the amino
acid properties. However, R42 and E84 introduce a positive and
a negative charge, respectively, at positions were only serine and
alanine, respectively, have been observed in other PLIαs.
In conclusion, a new myotoxin inhibitory protein, AnMIP,
has been isolated from the plasma of the snake A. nummifer and
classified as a PLIα, showing specificity towards group II
PLA2s from the venom of this and related crotaline species. Its
complete primary structure was deduced by molecular cloning.
Future studies will attempt its production in recombinant form
to overcome the limited availability from the natural source, and
to gain insight into the molecular mechanism(s) involved in its
myotoxin inhibitory activity.
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